Ultimovacs ASA (OSL:ULTI)
kr 7.45 -0.1 (-1.32%) Market Cap: 256.32 Mil Enterprise Value: 38.98 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 30/100

Q4 2020 Ultimovacs ASA Earnings Call Transcript

Feb 17, 2021 / 08:00AM GMT
Release Date Price: kr74.6 (-0.80%)
Carlos de Sousa
Ultimovacs ASA - CEO

Good morning, everybody, and welcome to Ultimovacs' fourth quarter 2020 presentation. Thank you for being here and for your interest in listening to what was a very successful quarter for Ultimovacs.

So let's move to the next slide, slide number 2. I need to show you the disclaimer. And now, moving to slide number 3. This is the agenda for today. I will start giving the highlights for the quarter. Then I will give the word to Jens to go through the operational update on our clinical trials.

Hans will cover the key financials and news flow. And then we will have -- as usually, we select a theme to explain and talk to our shareholders about some of the key topics that impact our activities in our industry. And we selected for this quarter talking about intellectual property rights and other ways of protecting the commercial interest of the company. And as usual, we will end with a Q&A session. So please make sure that you start sending your questions now through the link.

Moving to the next slide, slide number 4. So highlights for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot